No Data
No Data
Hailey Biotech (603718.SH) reported 2023 results, net profit of 62.882 million yuan, a year-on-year decrease of 48.30%
Hailey Biotech (603718.SH) released its 2023 annual report, achieving revenue of 241 million yuan, a year-on-year decrease of 19.76%. Net profit attributable to shareholders of listed companies was 62.882 million yuan, a year-on-year decrease of 48.30%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 11.8219 million, a year-on-year decrease of 52.36%. It is proposed to distribute a cash dividend of 0.287 yuan (tax included) for every 10 shares to all shareholders.
Express News | Hailey Biotech: Net loss of 3.7194 million yuan in the first quarter
A-share agricultural services continued to rise, and Hailey Biotech closed up and down
Gelonghui, March 21 | Haili Biotech closed, and Yongshun Biotech, Dayu Water Saving, Huisheng Biotech, Zhongmu Co., Ltd., and Xianfeng Holdings followed suit.
“Double random” spot checks were effective, and 8 company problems were revealed! Hailey Biotech and others announced the results of the Securities Regulatory Bureau's investigation
① Hailey Biotech announced tonight that the Shanghai Securities Regulatory Bureau has taken measures to issue a warning letter against the company and related responsible persons. ② According to an article published on the official website of the Shanghai Securities Regulatory Bureau in June last year, two random spot checks were carried out for on-site inspections of listed companies in Shanghai in 2023, and 8 random targets were selected; an article published in November last year showed that the inspection work was completed. ③ The reporter saw from the announcements of 8 listed companies that all had problems with credit disclosure.
Hailey Biotech (603718.SH) received a warning letter from the Shanghai Securities Regulatory Bureau
Hailey Biotech (603718.SH) issued an announcement. The company recently received a decision on administrative supervision measures from the Shanghai Securities Regulatory Bureau...
[BT Financial Report Instantaneous Analysis] Hailey Biotech's 2023 Quarterly Report Perspective: Seek New Opportunities Amidst Challenges, Significant Growth in Net Profit
Hailey Biotech (stock code: 603718) is a publicly traded company involved in both the veterinary biological products and in vitro diagnostic (IVD) industries. Faced with challenges such as industry reshuffling, environmental protection policies, anti-resistance measures, and African swine fever, Hailey Biotech has responded positively to maintain market competitiveness by increasing investment in R&D to improve product quality and technical service levels. At the same time, the company is also seizing the rapid development opportunities in the field of in vitro diagnostics, especially on tracks such as molecular diagnosis and POCT, and strives to enhance independent R&D and production capacity to adapt to the trend of domestic production substitution. In terms of assets and liabilities, according to the 2023 three-quarter report
No Data